You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH):控股子公司藥品通過仿製藥一致性評價

格隆匯8月4日丨聯環藥業(600513.SH)公佈,公司控股子公司新鄉常樂製藥有限責任公司(稱“常樂製藥”)於近日收到國家藥品監督管理局覈準簽發的關於鹽酸林可黴素注射液《藥品補充申請批準通知書》,批準常樂製藥本品通過仿製藥質量和療效一致性評價。鹽酸林可黴素注射液(規格:2ml:0.6g)屬林可酰胺類抗生素,臨牀適用於敏感菌所致的呼吸道感染、皮膚軟組織感染及骨關節感染等疾病。

鹽酸林可黴素注射液通過一致性評價,有利於擴大該藥品的市場份額,提升市場競爭力,上述《藥品補充申請批準通知書》的取得預計不會對公司近期經營業績產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account